InvestmentPitch Media Video Discusses FSD Pharma's Closing of its acquisition of Canadian Specialty Psychedelic Pharmaceutical Company Lucid Psycheceuticals - Video Available on Investmentpitch.com

About this update from Quantum Biopharma Ltd. Subordinate Voting Shares Class B

[{"type":"text","content":"InvestmentPitch Media Video Discusses FSD Pharma's Closing of its acquisition of Canadian Specialty Psychedelic Pharmaceutical Company Lucid Psycheceuticals - Video Available on Investmentpitch.comVancouver, British Columbia--(Newsfile Corp. - September 22, 2021) - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions in legal psychedelics and medical cannabis, has closed its acquisition of Lucid Psycheceuticals. Founded in 2020, Lucid Psycheceuticals (www.LucidPsycheceuticals.com), a Canadian-based specialty psychedelic pharmaceutical company, is developing novel molecules and combinations with the goal of addressing Total Brain Health and targeting some of the most challenging neurodegenerative diseases, such as Multiple Sclerosis, Alzheimer's disease and Parkinson's disease.Cannot view this video? Visit:http://www.investmentpitch.com/video/1_s4o55wdg/FSD-Pharma-closed-its-acquisition-of-Canadian-specialty-psychedelic-pharmaceutical-company-Lucid-PsycheceuticalsInvestmentPitch.com has produced a \"video\" which discusses this news. If this link is not enabled, please visit www.InvestmentPitch.com and enter \"FSD Pharma\" in the search box. To close the acquisition, FSD Pharma is issuing approximately US$9 million or CDN$11.3 million in FSD Pharma stock.Lucid's co-founder and CEO, Dr. Lakshmi Kotra is taking on the role CEO of Lucid, which will be the Company's wholly-owned subsidiary. In that newly created role, he will continue to assess and advance FSD Pharma's innovative drug development programs. Dr. Kotra is a Professor of Medicinal Chemistry at the University of Toronto, and senior scientist at Krembil Brain Institute at the University Health Network.Anthony Durkacz, Interim CEO, stated, \"The acquisition of Lucid represents a positive and exciting step in pursuit of our strategic objectives at FSD Pharma, as we advance a diversified pipeline of novel, patent-protected drug candidates. These are leading edge molecules to target therapies for mental health disorders and neurodegenerative diseases in a totally unique way, through the regulatory process. We are excited that Dr. Kotra, an award-winning researcher and accomplished executive with experience in drug discovery and clinical development, will now be leading this eff...

More updates from Quantum Biopharma Ltd. Subordinate Voting Shares Class B